RNA interference (RNAi) holds great promise for the treatment of inherited and acquired diseases, provided that safe and efficient delivery systems are available. Herein we report that structurally flexible triethanolamine (TEA) core PAMAM dendrimers are able to deliver an Hsp27 siRNA effectively into prostate cancer (PC-3) cells by forming stable nanoparticles with siRNA, protecting the siRNA nanoparticles from enzymatic degradation, and enhancing cellular uptake of siRNA. The Hsp27 siRNA resulted in potent and specific gene silencing of heat-shock protein 27, an attractive therapeutic target in castrate-resistant prostate cancer. Silencing of the hsp27 gene led to induction of caspase-3/7-dependent apoptosis and inhibition of PC-3 cell gr...
International audienceCurrently, RNAi based approaches for cancer treatment involving short double s...
Background: The advancement of gene silencing via RNA interference is limited by the lack of effecti...
International audienceSmall interfering RNA (siRNA) is emerging as a novel therapeutic for treating ...
Successful achievement of RNA interference in therapeutic applications requires safe and efficient v...
Prostate cancer (PCa) accounts for a high number of deaths in males with no available curative treat...
International audienceGenuine, nondegraded PAMAM dendrimers self-assemble with siRNA into nanoscale ...
International audienceThis paper examines a perspective to use newly engineered nanomaterials as eff...
Cancer remains the second leading cause of death in the United States, despite significant advances ...
Successful therapeutic implementation of RNA interference critically depends on systems able to safe...
International audienceMetastasis is the cause of most (>90%) cancer deaths and currently lacks effec...
Guanhua Li,1,2 Zuojun Hu,1 Henghui Yin,1 Yunjian Zhang,1 Xueling Huang,1 Shenming Wang,1 Wen Li2 1De...
The recently discovered small interfering RNA (siRNA) holds great promise in cancer therapy. However...
The transferrin (TfR) and epidermal growth factor receptors (EGFR) are known to be overexpressed on ...
Objective(s): Breast cancer is the second leading cause of cancer death in females. Understanding mo...
Our purpose was to develop a new pharmacological approach for the treatment of prostate cancer (PCa)...
International audienceCurrently, RNAi based approaches for cancer treatment involving short double s...
Background: The advancement of gene silencing via RNA interference is limited by the lack of effecti...
International audienceSmall interfering RNA (siRNA) is emerging as a novel therapeutic for treating ...
Successful achievement of RNA interference in therapeutic applications requires safe and efficient v...
Prostate cancer (PCa) accounts for a high number of deaths in males with no available curative treat...
International audienceGenuine, nondegraded PAMAM dendrimers self-assemble with siRNA into nanoscale ...
International audienceThis paper examines a perspective to use newly engineered nanomaterials as eff...
Cancer remains the second leading cause of death in the United States, despite significant advances ...
Successful therapeutic implementation of RNA interference critically depends on systems able to safe...
International audienceMetastasis is the cause of most (>90%) cancer deaths and currently lacks effec...
Guanhua Li,1,2 Zuojun Hu,1 Henghui Yin,1 Yunjian Zhang,1 Xueling Huang,1 Shenming Wang,1 Wen Li2 1De...
The recently discovered small interfering RNA (siRNA) holds great promise in cancer therapy. However...
The transferrin (TfR) and epidermal growth factor receptors (EGFR) are known to be overexpressed on ...
Objective(s): Breast cancer is the second leading cause of cancer death in females. Understanding mo...
Our purpose was to develop a new pharmacological approach for the treatment of prostate cancer (PCa)...
International audienceCurrently, RNAi based approaches for cancer treatment involving short double s...
Background: The advancement of gene silencing via RNA interference is limited by the lack of effecti...
International audienceSmall interfering RNA (siRNA) is emerging as a novel therapeutic for treating ...